Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy is a Traditional Chinese Medicine (TCM) protocol developed by the Guangdong Provincial Hospital of Chinese Medicine for the treatment of rheumatoid arthritis (RA). It consists of two distinct formulations: **Zhuanbing Fang** (a specialized hospital-developed formula for RA) and **Shenling Baizhu Powder** (a classic TCM prescription). The combination is specifically indicated for RA patients presenting with the 'Spleen Deficiency and Dampness-Heat' syndrome. Zhuanbing Fang typically contains potent anti-inflammatory herbs such as *Tripterygium wilfordii*, which target synovial inflammation and pro-inflammatory cytokines. Shenling Baizhu Powder is used to tonify the Spleen, resolve dampness, and improve gastrointestinal tolerance, which is often compromised in RA patients due to both the disease process and the side effects of conventional disease-modifying antirheumatic drugs (DMARDs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhuanbing fang + shenling baizhu powder.